↓ Skip to main content

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations

Overview of attention for article published in Alzheimer's Research & Therapy, October 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
8 tweeters

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
69 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
Published in
Alzheimer's Research & Therapy, October 2017
DOI 10.1186/s13195-017-0313-3
Pubmed ID
Authors

Ronald Lautner, Philip S. Insel, Tobias Skillbäck, Bob Olsson, Mikael Landén, Giovanni B. Frisoni, Sanna-Kaisa Herukka, Harald Hampel, Anders Wallin, Lennart Minthon, Oskar Hansson, Kaj Blennow, Niklas Mattsson, Henrik Zetterberg

Abstract

From earlier studies it is known that the APOE ε2/ε3/ε4 polymorphism modulates the concentrations of cerebrospinal fluid (CSF) beta-amyloid1-42 (Aβ42) in patients with cognitive decline due to Alzheimer's disease (AD), as well as in cognitively healthy controls. Here, in a large cohort consisting solely of cognitively healthy individuals, we aimed to evaluate how the effect of APOE on CSF Aβ42 varies by age, to understand the association between APOE and the onset of preclinical AD. APOE genotype and CSF Aβ42 concentration were determined in a cohort comprising 716 cognitively healthy individuals aged 17-99 from nine different clinical research centers. CSF concentrations of Aβ42 were lower in APOE ε4 carriers than in noncarriers in a gene dose-dependent manner. The effect of APOE ε4 on CSF Aβ42 was age dependent. The age at which CSF Aβ42 concentrations started to decrease was estimated at 50 years in APOE ε4-negative individuals and 43 years in heterozygous APOE ε4 carriers. Homozygous APOE ε4 carriers showed a steady decline in CSF Aβ42 concentrations with increasing age throughout the examined age span. People possessing the APOE ε4 allele start to show a decrease in CSF Aβ42 concentration almost a decade before APOE ε4 noncarriers already in early middle age. Homozygous APOE ε4 carriers might deposit Aβ42 throughout the examined age span. These results suggest that there is an APOE ε4-dependent period of early alterations in amyloid homeostasis, when amyloid slowly accumulates, that several years later, together with other downstream pathological events such as tau pathology, translates into cognitive decline.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 69 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 11 16%
Student > Master 11 16%
Researcher 7 10%
Student > Bachelor 6 9%
Other 5 7%
Other 10 14%
Unknown 19 28%
Readers by discipline Count As %
Neuroscience 10 14%
Medicine and Dentistry 7 10%
Biochemistry, Genetics and Molecular Biology 6 9%
Psychology 6 9%
Agricultural and Biological Sciences 5 7%
Other 10 14%
Unknown 25 36%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 July 2018.
All research outputs
#3,536,983
of 13,199,565 outputs
Outputs from Alzheimer's Research & Therapy
#423
of 581 outputs
Outputs of similar age
#98,307
of 311,232 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#65
of 95 outputs
Altmetric has tracked 13,199,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 581 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.9. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,232 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.